Literature DB >> 20415716

Angiogenesis and lymphangiogenesis in bronchial asthma.

A Detoraki1, F Granata, S Staibano, F W Rossi, G Marone, A Genovese.   

Abstract

Neovascularization plays a prominent role in inflammation and tissue remodeling in several chronic inflammatory disorders. Vessel number and size, vascular surface area and vascular leakage are all increased in biopsies from patients with asthma. High levels of VEGF and other angiogenic factors have been detected in tissues and biological samples of patients with asthma and correlate with disease activity and inversely with airway hyper-responsiveness. Inflammation in the lung stimulates the growth of new blood vessels and these contribute to the airway obstruction or airway hyper-responsiveness, or both. Effector cells of inflammation (human lung mast cells, basophils, eosinophils, macrophages, etc.) are major sources of a vast array of angiogenic and lymphangiogenic factors. Inhaled corticosteroids reduce vascularity and growth factor expression and might modulate bronchial vascular remodeling in asthma. Specific antagonists to VEGF and other angiogenic factors and their receptors might help to control chronic airway inflammation and vascular remodeling and offer a novel approach for the treatment of chronic inflammatory lung disorders.

Entities:  

Mesh:

Year:  2010        PMID: 20415716     DOI: 10.1111/j.1398-9995.2010.02372.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  47 in total

Review 1.  Dynamics of airway blood vessels and lymphatics: lessons from development and inflammation.

Authors:  Donald M McDonald; Li-Chin Yao; Peter Baluk
Journal:  Proc Am Thorac Soc       Date:  2011-11

Review 2.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

Review 3.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

4.  Markers of vascular perturbation correlate with airway structural change in asthma.

Authors:  Mats W Johansson; Stanley J Kruger; Mark L Schiebler; Michael D Evans; Ronald L Sorkness; Loren C Denlinger; William W Busse; Nizar N Jarjour; Robert R Montgomery; Deane F Mosher; Sean B Fain
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

Review 5.  The immune network in thyroid cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

6.  YAP1, targeted by miR-375, enhanced the pro-angiogenesis of airway smooth muscle cells in asthma via STAT3 activation.

Authors:  Long Zhao; Xiaolan Shi; Ning Wang; Cuicui Liu; Jing Wang
Journal:  Cell Cycle       Date:  2020-04-19       Impact factor: 4.534

Review 7.  Carcinogenesis: the cancer cell-mast cell connection.

Authors:  Maria-Angeles Aller; Ana Arias; Jose-Ignacio Arias; Jaime Arias
Journal:  Inflamm Res       Date:  2018-11-20       Impact factor: 4.575

Review 8.  Vascular endothelial growth factor as a key inducer of angiogenesis in the asthmatic airways.

Authors:  Norbert Meyer; Cezmi A Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 9.  Eosinophil-derived cytokines in health and disease: unraveling novel mechanisms of selective secretion.

Authors:  R C N Melo; L Liu; J J Xenakis; L A Spencer
Journal:  Allergy       Date:  2013-01-25       Impact factor: 13.146

10.  Fatty acid binding protein 4 regulates VEGF-induced airway angiogenesis and inflammation in a transgenic mouse model: implications for asthma.

Authors:  Elisa Ghelfi; Chen-Wei Yu; Harun Elmasri; Matthew Terwelp; Chun G Lee; Vineet Bhandari; Suzy A Comhair; Serpil C Erzurum; Gökhan S Hotamisligil; Jack A Elias; Sule Cataltepe
Journal:  Am J Pathol       Date:  2013-02-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.